Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04833049 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04833049: Completed Phase 1 study, sponsored by Takeda.
NCT04833049 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04833049, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The aim of this study is to understand how TAK-994 is processed by the body. This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.
Interventions
- DRUG TAK-994 Oral Tablet
- DRUG [14C]TAK-994 Intravenous Infusion
- DRUG [14C]TAK-994 Oral Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2021-06-20 |
| Phase | Phase 1 |
What the finished NCT04833049 record still lists
NCT04833049 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which TAK-994 Oral Tablet is the first listed.
NCT04833049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04833049 about?
NCT04833049 is a clinical study titled "Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults". The aim of this study is to understand how TAK-994 is processed by the body. This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.
What is the current status of trial NCT04833049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-04-14. Estimated completion is 2021-06-20.
What interventions are being tested in trial NCT04833049?
The interventions under investigation include: TAK-994 Oral Tablet (DRUG), [14C]TAK-994 Intravenous Infusion (DRUG), [14C]TAK-994 Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT04833049?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04833049's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI